Status:

COMPLETED

Imaging the Neurobiology of a Behavioral Treatment for Cocaine Dependence

Lead Sponsor:

New York State Psychiatric Institute

Collaborating Sponsors:

National Institute on Drug Abuse (NIDA)

Conditions:

Cocaine Dependence

Eligibility:

All Genders

21-45 years

Phase:

NA

Brief Summary

The purpose of this study is to determine whether patients with the greatest loss of dopamine transmission due to cocaine dependence at pre-treatment PET and MRI scans will be those who fail to respon...

Detailed Description

Previous studies have shown that cocaine dependence is associated with a decrease in dopamine release in response to a psychostimulant challenge. We have recently completed a study demonstrating that ...

Eligibility Criteria

Inclusion

  • Males or females between 21 and 45 years old
  • Fulfill DSMIV criteria for cocaine abuse or dependence
  • Able to give informed consent and comply with study procedures
  • Medically Healthy

Exclusion

  • Major DSM-IV Axis I disorder other than cocaine abuse or dependence. Subjects with a history of other psychostimulant abuse/dependence or compulsive gambling will be excluded.
  • Current use of opiates, sedative-hypnotic, and/or cannabis more than twice a week (use less than twice a week is acceptable).
  • Current use of psychotropic medication such as antipsychotics or antidepressants.
  • Presence or positive history of severe medical or neurological illness (including epilepsy), or any cardiovascular disease, low hemoglobin (Hb \< 14 gm/dL in males, Hb \< 12 gm/dL in females), or SGOT or SGPT \> 2-3 times normal. Chronic active hepatitis B or C will also be an exclusion criteria.
  • Resting SBP \>150, DBP \> 90
  • Pregnancy or lactation, lack of effective birth control during 15 days before the scans\*
  • Evidence /report of any heart abnormality during intake medical history, EKG or physical exam.
  • Metal implants or paramagnetic objects contained within the body which may interfere with the MRI scan, as determined in consultation with a neuroradiologist and according to the guidelines set forth in the following reference book commonly used by neuroradiologists: "Guide to MR procedures and metallic objects" Shellock, PhD, Lippincott Williams and Wilkins, NY 2001.
  • Lifetime exposure to radiation in the workplace, or history of participation in nuclear medicine procedures, including research protocols \*\*
  • Positive Allen Test indicating lack of collateral blood flow to hand
  • History of sensitivity to methylphenidate

Key Trial Info

Start Date :

July 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2011

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT00376558

Start Date

July 1 2006

End Date

January 1 2011

Last Update

July 1 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

New York State Psychiatric Institute

New York, New York, United States, 10032